Resistance 2011 - 6th International Workshop on Hepatitis C - Resistance and New Compounds

Abstract submission

Abstract submission will be possible until 1 May. Only abstracts that are received before 1 May 2011 will be considered for review.

General guidelines

Abstracts should contain the following four components:

Background: a concise statement of the issue under investigation or a hypothesis;
Material & Methods: the experimental methods used (including the statistical analyses employed);
Results: specific findings (promises such as "to be completed" or "to be presented" are not acceptable); and
Conclusions: a summary of findings that are supported by your results (statistical analyses used to support the conclusions, where appropriate, should be included; concluding statements such as "the results will be discussed" are not acceptable).

Please note that abstracts cannot be accepted if tables or graphs are included.

The maximum word count for the abstract body is 500 words.

Abstracts are considered official communications to the conference and will be treated confidentially. For those abstracts that are accepted, submitters agree to attend the meeting and present their abstract as scheduled.

Policy regarding the inclusion of chemical structures

Since this workshop is dedicated to discussion of new HCV antivirals and the development of drug resistance, the inclusion of the chemical structures of new compounds in presentations is considered germane to the scientific discussion, and is strongly encouraged. Under some circumstances where the specific structure of a lead compound cannot be disclosed, substitution of a more generic structure which provides information on a compound series may be appropriate.

Abstract submission

Authors can submit their abstracts electronically per 1 March 2011 using the button on the right hand side. This will direct you to the appropriate webpage.

Please follow the step-by-step directions to upload the abstract. To ensure your abstract retains any special characters or formatting, the abstract must be in Microsoft Word format.

Categories for abstract submission

For purposes of review and programming, abstracts are divided into topical categories. Selection of the most appropriate category is important as it determines who reviews your abstract. The Program Committee reserves the right to reassign your abstract to a more appropriate category.

Topics

- Novel HCV inhibitors

- Novel drug development strategies

- Technologies for assessment of resistance

- HCV replication dynamics and pathogenesis

- Mechanisms of resistance selection and evolution

- Clinical relevance and management of HCV drug resistance

Notification of abstract acceptance and presentation format

Notifications of acceptance and format of presentation (oral or poster presentation) will be e-mailed (or faxed if you did not supply an e-mail address) to submitting author in the 3rd week of May.

It is the responsibility of the corresponding/presenting author to inform all co-authors of the abstract’s status. Please notify the Conference Secretariat if you have not received notification by the end of May.

If your abstract is accepted, one author is required to register for the conference and present the paper as scheduled. Guidelines for preparing your oral and/or poster presentations will be sent after your abstract has been accepted.

Abstract publication

Accepted abstracts will be published in the Final Program and Abstract Book, which will be distributed during the conference. In addition, all abstracts will be published in the journal Reviews in Antiviral Therapy. Please note that the conference secretariat cannot be held responsible for any typing or language errors in the submitted abstracts as only the format of the abstracts will be changed and not the content.